-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Monte Rosa Therapeutics, Raises Price Target to $37

Benzinga·01/14/2026 14:49:39
Listen to the news
Piper Sandler analyst Edward Tenthoff reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and raises the price target from $27.5 to $37.